This task order involves the manufacturing of a unique multi-antigen plasmid DNA vaccine. Elements of the work include the production of the drug substance and the drug product. The production of this vaccine is a multi-step process consisting of generating working cell banks, process development to purify the plasmid, verification of plasmids by next gen sequencing. The drug substance is formulated in a buffer system prior to filling. The initial development runs are done under lab conditions in a research and development environment. However, the follow-up processes to produce product suitable for human use are performed under cGMP.